DEF: Y-mAbs Therapeutics Announces 2025 Annual Meeting and Director Nomination

Y-mAbs Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on July 11, 2025, to vote on director election, auditor ratification, and executive compensation.

Summary

• Y-mAbs Therapeutics will hold its 2025 Annual Meeting of Stockholders on July 11, 2025, at 8:00 a.m. Eastern Time, conducted entirely online.
• Stockholders of record as of May 23, 2025, are entitled to vote.
• The meeting will address the election of one Class I director, David N. Gill, until the 2028 annual meeting.
• Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, will be voted on.
• A non-binding advisory vote on the compensation of the company’s named executive officers will occur.
• The Board of Directors recommends voting FOR the director nominee, FOR the ratification of the accounting firm, and FOR the executive compensation proposal.
• The Board of Directors approved a reduction in the number of directors constituting the full Board of Directors from eight to seven, effective immediately prior to the Annual Meeting.

Sentiment

Score: 7

Explanation: The document is a standard SEC filing for an annual meeting, presenting routine proposals. The tone is generally positive, with recommendations for voting in favor of the proposals. The sentiment score reflects the neutral to slightly positive nature of the information.

Positives

• The Board of Directors recommends voting FOR the election of David N. Gill as Class I director.
• The Board of Directors recommends voting FOR the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm.
• The Board of Directors recommends voting FOR the approval of the compensation of the company’s named executive officers.
• Approximately 97% of the votes cast at the 2024 Annual Meeting of Stockholders were in favor of the proposal related to compensation practices for 2023.

Negatives

• The Board of Directors did not nominate Dr. Tagliaferri for re-election.
• The Board of Directors approved a reduction in the number of directors constituting the full Board of Directors from eight to seven, effective immediately prior to the Annual Meeting.

Risks

• The document does not explicitly list any risks.

Future Outlook

The Board of Directors and the Compensation Committee will evaluate actions to address stockholder concerns based on the advisory vote on executive compensation.

Management Comments

• Michael Rossi, President and Chief Executive Officer: 'Thank you for your ongoing support and continued interest in the Company. We look forward to receiving your vote in respect of the business to be conducted at the Annual Meeting.'

Industry Context

The document relates to the governance and shareholder engagement practices common among publicly traded companies, particularly in the biopharmaceutical industry.

Comparison to Industry Standards

• The document does not explicitly compare the company's performance to industry standards or benchmarks.
• The document does reference a peer group of companies used for compensation benchmarking, including Aadi Bioscience, Inc., Agios Pharmaceuticals, Inc., Arcus Biosciences, Inc., Atara Biotherapeutics, Inc., BioCryst Pharmaceuticals, Inc., bluebird bio, Inc., Deciphera Pharmaceuticals, Inc., G1 Therapeutics, Inc., Heron Therapeutics, Inc., Iovance Biotherapeutics, Inc., Karyopharm Therapeutics Inc., MacroGenics, Inc., Puma Biotechnology , Inc., Rhythm Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., SpringWorks Therapeutics, Inc., Travere Therapeutics, Inc., and UroGen Pharma Ltd.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Impacted by decisions on director election, auditor ratification, and executive compensation.
• Employees: Impacted by decisions on executive compensation and corporate governance.
• Customers: No direct impact mentioned in the document.
• Suppliers: No direct impact mentioned in the document.
• Creditors: No direct impact mentioned in the document.

Next Steps

• Stockholders to vote on the proposals outlined in the proxy statement.
• The company to hold the Annual Meeting on July 11, 2025.
• The Board of Directors and Compensation Committee to evaluate actions based on the outcome of the advisory vote on executive compensation.

Key Dates

Recommendation

Keywords

Annual Meeting, Proxy Statement, Director Election, Executive Compensation, Auditor Ratification, Corporate Governance, Y-mAbs Therapeutics